Greenwich LifeSciences wins EMA clearance to combine HLA patient groups in FLAMINGO-01 trial

Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc.

GLSI

0.00
  • Greenwich LifeSciences secured European Medicines Agency clearance to enroll HLA-A02 and non-HLA-A02 patients in the same randomized arms of FLAMINGO-01.
  • Protocol alignment enables all 170-180 US and European sites to enroll both groups through the first interim analysis, boosting enrollment capacity.
  • Company now targets a combined analysis to support potential approval across both HLA populations, expanding the addressable market for GP2.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenwich Lifesciences Inc. published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.